Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial
G. Raghu (Seattle, United States of America), O. Distler (Zurich, Switzerland), A. Azuma (Tokyo, Japan), A. Fischer (Denver, Colorado, United States of America), K. Highland (Cleveland, Ohio, United States of America), M. Kuwana (Tokyo, Japan), M. Mayes (Houston, Texas, United States of America), D. Wachtlin (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), M. Alves (Ingelheim am Rhein, Germany), M. Gahlemann (Basel, Switzerland), T. Maher (London , United Kingdom)
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Raghu (Seattle, United States of America), O. Distler (Zurich, Switzerland), A. Azuma (Tokyo, Japan), A. Fischer (Denver, Colorado, United States of America), K. Highland (Cleveland, Ohio, United States of America), M. Kuwana (Tokyo, Japan), M. Mayes (Houston, Texas, United States of America), D. Wachtlin (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), M. Alves (Ingelheim am Rhein, Germany), M. Gahlemann (Basel, Switzerland), T. Maher (London , United Kingdom). Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial. 5193
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: